Home | About | Archives | RSS Feed |
@theMarket: New Year Markets Begin With Profit-Taking
Investors were greeted with a brutal bout of selling as 2024 unfolded this week. The stocks that had gained the most last year were obvious targets. Is this the end of the rally or is this simply a minor bump in the road?
The Santa Rally reversed, and the Grinch stomped on investors' hopes for further gains. The NASDAQ led stocks lower with the Magnificent Seven taking it on the chin. For those who believe in the idea that the first five trading days of January forecast the direction of the market for January and for the year overall, the market’s performance does not fill one with confidence.
It is nail-biting time for the bulls. The first three trading days of the year were negative. That has happened 12 times since 1950. Only three times has the market managed to turn positive by day 5. To me, the jury is out until the market closes on Jan. 8.
As for the disappointment that Santa did not come to Wall Street this year, let's look at history. Over the last 80 years, there have been 15 times where we have had negative results over the last five days of December and the first two days of the following January. Out of those 15 times, the market managed to deliver positive returns 10 times with a median return of 3 percent.
From a technical point of view, the sell-off did not even dent the bullish cast of the markets. As I have written over the last few weeks, the markets were overheated and each day we gained that condition worsened. The good news is that the selling has relieved that overbought condition without seriously impacting the upward momentum of the markets.
Even as the markets declined, some of the areas that lagged the markets during 2023 moved higher. The health-care sector, for example, saw some great gains, as did energy stocks and utilities. Those areas underperformed the markets drastically last year.
While most readers are focused on stocks, the main drivers of the last two months' gains have been the steep decline in bond yields and the declining dollar. Both areas have reversed this week with the benchmark Ten-Year U.S. Treasury bond seeing its yield break above 4 percent this week on the upside. And as we know, bond yields up usually mean stocks are down. Assets that are on the other side of the dollar (precious metals, materials, crypto, emerging markets) were hurt as well.
I am sure one of the reasons this occurred was a reverse in sentiment by bond traders. The betting on future interest rate cuts in 2024 had gotten out of hand, in my opinion. Some were betting up to six rate cuts in the year beginning in March. That to me was a case of irrational exuberance. Just because the Fed may have finished raising interest rates does not automatically mean the central bank will start cutting rates. In other words, the Fed's "higher for longer" is still the name of the game.
The economic news certainly did not support the need for the Fed to cut interest rates anytime soon. The economy is growing. Unemployment is not rising. Instead, the jobs market, per Friday's non-farm payrolls, surprised economists on the upside. The economy added 216,000 jobs, which was a big beat compared to the forecasts of 175,000 jobs.
On a different subject, the U.S. government was also responsible for some big price movements in two sectors this week: crypto and pot stocks. The Securities and Exchange Commission (SEC) has until Jan. 10 to rule on a proposal by Ark Invest and 21Shares. Both firms are applying to issue a bitcoin spot currency exchange-traded fund. Many other big brokers and asset managers such as Fidelity, Invesco, BlackRock, Van Eck, Wisdomtree, and more have done the same.
The SEC could reject the proposed application outright, delay it, or approve it. It looks to be a binary event that should send Bitcoin substantially higher (or lower) depending on the outcome. The betting ranges from 90 percent approval to zero chance.
On Wednesday, an October 2023 letter from the Drug Enforcement Administration (DEA) to a member of Congress, was revealed. It made clear that the agency had "the final authority to schedule, reschedule, or deschedule" drugs under the Controlled Substances Act (CSA). The DEA also told lawmakers it is "now conducting its review" of whether to soften federal regulation of marijuana under the CSA. The news instantly sent marijuana stocks higher.
Last year, I wrote that the Department of Health and Human Services had asked the DEA to review marijuana's Schedule 1 status and to reduce it to a Schedule III substance. That request triggered a huge run in the sector. This was largely due to the differential in federal taxes that would occur if the DEA granted marijuana Schedule III status. The industry would immediately experience a large decline in taxes leading to a big jump in profitability.
At the time, Industry experts believed that the DEA review would only happen in the second half of the year and closer to the elections. I advised readers not to chase the stocks, but rather wait until investor attentions were focused elsewhere. That happened. Hopefully, you were able to pick up some stocks or an ETF on the cheap.
Fortunately, some of that fluff has now come out of the markets, which to me is a positive development. I think we now have a chance to see new highs over the next week or two. However, that does not mean that we are up, up, and away into the rest of the first quarter. I am still expecting a more savage decline sometime soon that could begin as early as late January, or early February.
Bill Schmick is the founding partner of Onota Partners, Inc., in the Berkshires. His forecasts and opinions are purely his own and do not necessarily represent the views of Onota Partners Inc. (OPI). None of his commentary is or should be considered investment advice. Direct your inquiries to Bill at 1-413-347-2401 or email him at bill@schmicksretiredinvestor.com.
Anyone seeking individualized investment advice should contact a qualified investment adviser. None of the information presented in this article is intended to be and should not be construed as an endorsement of OPI, Inc. or a solicitation to become a client of OPI. The reader should not assume that any strategies or specific investments discussed are employed, bought, sold, or held by OPI. Investments in securities are not insured, protected, or guaranteed and may result in loss of income and/or principal. This communication may include opinions and forward-looking statements, and we can give no assurance that such beliefs and expectations will prove to be correct. Investments in securities are not insured, protected, or guaranteed and may result in loss of income and/or principal. This communication may include opinions and forward-looking statements, and we can give no assurance that such beliefs and expectations will prove to be correct.